The FDA recently granted breakthrough therapy designation to GSK5764227 (GSK’227), a novel B7-H3-targeted ADC, for two indications: relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC) in December 2024 and relapsed or refractory osteosarcoma in August 2024. This evidence concerns the gene CD276 and small cell lung carcinoma.